MediWound Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MediWound stock.
View analyst ratings for MediWound or view top-rated stocks.

Wall Street analysts have given MediWound a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MediWound wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

MediWound is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for MediWound.

MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. The biopharmaceutical company earned $5.85 million during the quarter, compared to analyst estimates of $5.30 million. MediWound had a negative trailing twelve-month return on equity of 125.38% and a negative net margin of 41.37%.
View MediWound's earnings history.

MediWound's stock was trading at $2.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MDWD shares have increased by 116.0% and is now trading at $4.99.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 1 year price targets for MediWound's stock. Their forecasts range from $6.00 to $10.00. On average, they expect MediWound's stock price to reach $7.50 in the next year. This suggests a possible upside of 50.3% from the stock's current price.
View analysts' price targets for MediWound or view top-rated stocks among Wall Street analysts.

Some companies that are related to MediWound include Canopy Rivers (RIV), Natural Alternatives International (NAII), Mannatech (MTEX), FitLife Brands (FTLF), Nutra Pharma (NPHC), Happiness Biotech Group (HAPP), Glucose Health (GLUC), Tauriga Sciences (TAUG), Cyanotech (CYAN), Heyu Biological Technology (HYBT), GLG Life Tech (GLGLF), Exactus (EXDI), Entia Biosciences (ERGO), Rock Creek Pharmaceuticals (RCPIQ) and Beleave (BE).
View all of MDWD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), The Blackstone Group (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

MediWound's stock is owned by many different retail and institutional investors. Top institutional investors include Migdal Insurance & Financial Holdings Ltd. (5.63%), Renaissance Technologies LLC (2.54%), Parian Global Management LP (2.53%), Sargent Investment Group LLC (1.34%), Essex Investment Management Co. LLC (1.22%) and Acadian Asset Management LLC (1.00%).

MDWD stock was sold by a variety of institutional investors in the last quarter, including Migdal Insurance & Financial Holdings Ltd..

MDWD stock was acquired by a variety of institutional investors in the last quarter, including Parian Global Management LP, Essex Investment Management Co. LLC, JPMorgan Chase & Co., Renaissance Technologies LLC, BOKF NA, Sargent Investment Group LLC, Acadian Asset Management LLC, and Citadel Advisors LLC.

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDWD stock can currently be purchased for approximately $4.99.

MediWound has a market capitalization of $135.91 million and generates $21.76 million in revenue each year. The biopharmaceutical company earns $-9,200,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

MediWound employs 75 workers across the globe.

The official website for MediWound is www.mediwound.com.

MediWound is headquartered at 42 HAYARKON STREET, YAVNE L3, 8122745.

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]